Cargando…

Efficacy and safety of rituximab biosimilar in refractory lupus

AIMS: To characterise patients with refractory SLE receiving rituximab biosimilar (CT-P10) and to explore short-term efficacy and safety associated with rituximab biosimilar use. METHODS: We retrospectively analysed data from the medical records of patients with refractory SLE who received CT-P10 in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pongtarakulpanit, Nantakarn, Pisitkun, Prapaporn, Ngamjanyaporn, Pintip
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Brief Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7607610/ https://www.ncbi.nlm.nih.gov/pubmed/33139454 http://dx.doi.org/10.1136/lupus-2020-000442

Ejemplares similares

2222. A study of the role of trimethoprim-sulfamethoxazole in opportunistic infection prevention in lupus patients taking low-level immunosuppressive treatment: An open-labeled, randomized controlled trial
por: Munthananuchat, Paopat, et al.
Publicado: (2023)

The model of circulating immune complexes and interleukin-6 improves the prediction of disease activity in systemic lupus erythematosus
por: Thanadetsuntorn, Chokchai, et al.
Publicado: (2018)

2684. The Prospective Pilot Study of Infectious Complication Surveillance in Active Systemic Lupus Erythematosus Patients with Intense Immunosuppressive Therapy: Cellular Response and Clinical Outcomes
por: Rotjanapan, Porpon, et al.
Publicado: (2019)

2655. A Prospective Study of Cytomegalovirus Infection in Active Systemic Lupus Erythematosus Patients with Intense Immunosuppressive Therapy: Epidemiology, Associated Risk Factors, Pathogenesis, and Clinical Outcomes
por: Bushyakanist, Asalaysa, et al.
Publicado: (2019)

1147. A study of high-dose influenza vaccination responses compared to standard-dose in lupus patients: an open- labeled, randomized controlled study
por: Yingyounyong, Sasicha, et al.
Publicado: (2023)

Prospective Pilot Study of Cyclophosphamide as an Adjunct Treatment in Patients With Adult-Onset Immunodeficiency Associated With Anti-interferon-γ Autoantibodies
por: Laisuan, Wannada, et al.
Publicado: (2020)

280. A cross-sectional pilot study on the relationship of gut microbiota pattern to immunogenicity of influenza vaccine in lupus patients
por: Kiewsanuan, Nathathai, et al.
Publicado: (2023)

Vaginal microbiota affects urinary tract infection risk in women with systemic lupus erythematosus: a pilot cross-sectional study from Thailand
por: Rotjanapan, Porpon, et al.
Publicado: (2021)

Predicting treatment response and clinicopathological findings in lupus nephritis with urine epidermal growth factor, monocyte chemoattractant protein-1 or their ratios
por: Ngamjanyaporn, Pintip, et al.
Publicado: (2022)

Performance of cytokine models in predicting SLE activity
por: Ruchakorn, Nopparat, et al.
Publicado: (2019)

The expansion of activated naive DNA autoreactive B cells and its association with disease activity in systemic lupus erythematosus patients
por: Wangriatisak, Kittikorn, et al.
Publicado: (2021)

Real world safety of CT-P10 (anti-CD 20 monoclonal antibodies biosimilar) in rheumatic and autoimmune diseases
por: Katchamart, Wanruchada, et al.
Publicado: (2022)

Health related quality of life in anti interferon γ autoantibody associated immunodeficiency syndrome measured with EQ5D5L and SF36
por: Temsangsukmanee, Jirat, et al.
Publicado: (2023)

Rituximab Biosimilar BCD020 Shows Superior Efficacy above Conventional Non-Biologics Treatment in Pediatric Lupus Nephritis: The Data of Retrospective Cohort Study
por: Kostik, Mikhail, et al.
Publicado: (2023)

CD4(+) T-cell cooperation promoted pathogenic function of activated naïve B cells of patients with SLE
por: Wangriatisak, Kittikorn, et al.
Publicado: (2022)

Efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus and lupus nephritis who are refractory to conventional therapy
por: Tanaka, Yoshiya, et al.
Publicado: (2016)

Meta-analysis of genome-wide association study identifies FBN2 as a novel locus associated with systemic lupus erythematosus in Thai population
por: Tangtanatakul, Pattarin, et al.
Publicado: (2020)

Trichoscopic Signs in Dermatomyositis, Systemic Lupus Erythematosus, and Systemic Sclerosis: A Comparative Study of 150 Patients
por: Chanprapaph, Kumutnart, et al.
Publicado: (2022)

Clinical efficacy and safety of rituximab in lupus nephritis
por: Zhong, Zhiqing, et al.
Publicado: (2019)

Safety of switching between rituximab biosimilars in onco-hematology
por: Urru, Silvana A. M., et al.
Publicado: (2021)

Biomarkers for Refractory Lupus Nephritis: A Microarray Study of Kidney Tissue
por: Benjachat, Thitima, et al.
Publicado: (2015)

A Prospective Study of Cytomegalovirus-Specific Cell-Mediated Immune Monitoring and Cytomegalovirus Infection in Patients With Active Systemic Lupus Erythematosus Receiving Immunosuppressants
por: Bruminhent, Jackrapong, et al.
Publicado: (2021)

Rituximab in refractory myasthenia gravis: a prospective, open‐label study with long‐term follow‐up
por: Anderson, Dustin, et al.
Publicado: (2016)

Biosimilars Have Arrived: Rituximab
por: Greenwald, Maria, et al.
Publicado: (2018)

Lupus-like Disease in FcγRIIB(−/−) Mice Induces Osteopenia
por: Visitchanakun, Peerapat, et al.
Publicado: (2019)

Rituximab in refractory Vogt–Koyanagi–Harada disease
por: Dolz-Marco, Rosa, et al.
Publicado: (2011)

Rituximab can Decrease Proteinuria in Refractory Lupus Nephritis
por: Suh, Chang-Hee
Publicado: (2022)

Efficacy and Safety of Rituximab in Korean Patients with Refractory Inflammatory Myopathies
por: Ahn, Ga Young, et al.
Publicado: (2020)

Safety and efficacy of rituximab in refractory pediatric Systemic Lupus Erythematosus nephritis: a single-center experience of northern Greece
por: Trachana, M, et al.
Publicado: (2011)

Biologicals and Biosimilars in Hematology: The Case of Rituximab
por: Vulto, Arnold G.
Publicado: (2019)

Zytux in Refractory Myasthenia Gravis: A Multicenter, Open-Labeled, Clinical Trial Study of Effectiveness and Safety of a Rituximab Biosimilar
por: Fatehi, Farzad, et al.
Publicado: (2021)

Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register
por: McCarthy, Eoghan M, et al.
Publicado: (2018)

Multicenter Retrospective Analysis of the Effectiveness and Safety of Rituximab in Korean Patients with Refractory Systemic Lupus Erythematosus
por: Bang, So-Young, et al.
Publicado: (2012)

Efficacy and Safety of Rituximab in Systemic Lupus Erythematosus and Sjögren Syndrome Patients With Refractory Thrombocytopenia: A Retrospective Study of 21 Cases
por: Jiang, Bin, et al.
Publicado: (2015)

Refractory Lupus Panniculitis Treated Successfully with Rituximab: Two Cases
por: Gupta, Partisha, et al.
Publicado: (2020)

Rituximab for Remission Induction and Maintenance in Refractory Systemic Lupus Erythematosus
por: Bonilla-Abadía, Fabio, et al.
Publicado: (2014)

Rituximab in the treatment of extensive and refractory subacute cutaneous lupus erythematosus
por: Penha, Mariana Álvares, et al.
Publicado: (2018)

Efficacy and Safety of Rituximab in Chinese Children With Refractory Anti-NMDAR Encephalitis
por: Dou, Xiangjun, et al.
Publicado: (2020)

Introduction of Biosimilar Rituximab: A Hospital Perspective
por: Cheesman, Simon
Publicado: (2020)

Rituximab biosimilars open new horizons in immunotherapy
por: Jaeger, Ulrich
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_i3cm4dhju98d5k6itus8lge3a6